Medacta Group S.A. (0A05) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, this is the Chorus Call Conference Operator. Welcome and thank you for joining the Medacta First Half 2025 Results Conference Call. As a reminder, all participants are in listen-only mode. After the presentation, there will be an opportunity to ask questions. Should anyone need assistance during the conference call, they may signal an operator by pressing star and zero on their telephone. At this time, I would like to turn the conference over to Mr. Francesco Sicardi, CEO of Medacta. Please go ahead, sir. Thank you very much, and good afternoon or good morning. Everybody, welcome to Medacta 2025 half-year results, conference call, and live webcast. The slides of today's presentation can be found on the Medacta Investor Relations website, along with the media releases. I would like to remind all participants that the presentation includes forward-looking statements which are subject to risk and uncertainties. And listeners and readers are therefore encouraged to refer to the disclaimer on slide two of today's presentation. And after those housekeeping remarks, I will now turn to slide four and start with the highlights of today's publication. We have already presented our top line H1 revenues, 344.1 million, corresponding to an increase in custom currency of 19.8%. Our adjusted EBDA margin for H1 in cost and currency reached 29.6%, which corresponds to a rise of 27.5% over last year period. The net profit for the period amounted to 60 million, a significant increase of 58% over H1 2024, And we confirm our outlook both for 2025 and our mid-term outlook. If we go on slide five, we can appreciate even more the considerable above-market revenue growth that Medact has been able to deliver over the last five years. This growth represents more than 4.5 times ...